Article

Intravitreal triamcinolone for AMD appears promising, but more studies needed

Author(s):

Laszlo Dosa

Fort Lauderdale, FL-Intravitreal triamcinolone appears to inhibit the growth of choroidal neovascularization (CNV) and reduce subretinal fluid in the short term, but it needs further evaluation, ac-cording to Mark Gillies, MB, BS, PhD.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Related Content
Harrow expands patient access to eyecare medications with price reductions and GoodRx partnership
November 23rd 2024

Harrow expands patient access to eyecare medications with price reductions and GoodRx partnership

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

CHMP issues positive opinion for the marketing authorization of FYB203, a biosimilar candidate to aflibercept
November 23rd 2024

CHMP issues positive opinion for the marketing authorization of FYB203, a biosimilar candidate to aflibercept

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Avant Technologies and Ainnova Tech partner to advance retinal camera with AI-driven diagnostic platform
November 22nd 2024

Avant Technologies and Ainnova Tech partner to advance retinal camera with AI-driven diagnostic platform

Integrating imaging modalities for early detection of key microscopic abnormalities in diabetic retinopathy
November 22nd 2024

Integrating imaging modalities for early detection of key microscopic abnormalities in diabetic retinopathy

© 2024 MJH Life Sciences

All rights reserved.